Practice-Changing Data in Prostate Cancer From ESMO 2023 Survival benefits using radioligand therapy and analyses identifying novel ways to better target treatment are among the prostate cancer ...

Novartis’ highly-touted radionuclide therapy Pluvicto met its primary endpoint in a phase 3 trial as a second-line therapy for PSMA-positive metastatic castration-resistant prostate cancer ...

Medscape Family Medicine, January 20, 2022 Clinical Advances in Prostate Cancer From ESMO 2021 Prof Johann de Bono discusses prostate cancer data from ESMO 2021, including abiraterone plus ...